ロード中...
Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer
Recent Phase III data presented at the American Society of Clinical Oncology (ASCO) 2013 annual conference by Brose et al led to the US Food and Drug Administration (FDA) approval of sorafenib for the treatment of well-differentiated radioactive iodine-resistant metastatic thyroid cancer. This is th...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4105272/ https://ncbi.nlm.nih.gov/pubmed/25053887 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S49430 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|